Disease · MONDO_0005433

alcohol withdrawal

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. alcohol withdrawal. Diseases, record MONDO_0005433. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005433

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: alcohol withdrawal
Open Targets ID: MONDO_0005433
Other names: alcohol withdrawal syndrome
Highest stage of its drugs: Phase 3, for 4 of its 22 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs22

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OXYTOCIN	CHEMBL395429	Protein	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
MAGNESIUM SULFATE	CHEMBL3989857	Small molecule	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
CHLORDIAZEPOXIDE	CHEMBL451	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LEVETIRACETAM	CHEMBL1286	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
GABAPENTIN	CHEMBL940	Small molecule	Phase 2/3	ClinicalTrials.gov	4	4	4	Drugs and targets
CANNABIDIOL	CHEMBL190461	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
FLUMAZENIL	CHEMBL407	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
THIAMINE	CHEMBL1588	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
LORAZEPAM	CHEMBL580	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ACAMPROSATE	CHEMBL1201293	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 22

See all 22 drugs

Targets79

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA1	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2562	Drugs and targets
GABRD	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2563	Drugs and targets

1 to 10 of 79

See all 79 targets

Trials21

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01184417	Phenobarbital for Acute Alcohol Withdrawal	Not applicable	102	2012-03-09	Alcohol Withdrawal	PHENOBARBITAL	Its record names the disease	ClinicalTrials.gov
NCT00597701	Treating Alcohol Withdrawal With Oral Baclofen	Not applicable	79	2011-07-26	Alcohol Withdrawal Delirium	BACLOFEN	Its record names the disease	ClinicalTrials.gov
NCT00262639	Prometa Protocol for Alcohol Dependence	Phase 2/3	60	2009-08-14	Alcohol Dependence	FLUMAZENIL, GABAPENTIN	Its record names the disease	ClinicalTrials.gov
NCT00106106	Acamprosate to Reduce Symptoms of Alcohol Withdrawal	Phase 2	56	2012-01-05	Alcohol-Related Disorders, Alcohol Dependence, Alcoholism, Healthy Volunteer	ACAMPROSATE	Its record names the disease	ClinicalTrials.gov
NCT01212185	Oxytocin Treatment of Alcohol Withdrawal	Phase 1	14	2014-05-13	Alcohol Withdrawal	OXYTOCIN	Its record names the disease	ClinicalTrials.gov
NCT01652326	Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome		792		Alcohol Withdrawal Syndrome	DIAZEPAM	Its record names the disease	ClinicalTrials.gov
NCT00136617	Outpatient Treatment of Alcohol Withdrawal Syndrome	Phase 3	165		Alcoholism, Alcohol Withdrawal	CHLORDIAZEPOXIDE	Its record names the disease	ClinicalTrials.gov
NCT00011297	Comparing Gabapentin and Lorazepam for Treating Alcohol Withdrawal	Phase 2	160		Alcoholism	GABAPENTIN	Its record names the disease	ClinicalTrials.gov
NCT00229125	Comparing the Treatment of Alcohol Withdrawal Syndrome Using Gabapentin Versus Lorazepam	Phase 2	160		Alcohol Withdrawal Syndrome(AWS)	GABAPENTIN, LORAZEPAM	Its record names the disease	ClinicalTrials.gov
NCT03466528	Alcohol: Thiamine and or Magnesium 1	Phase 2/3	127		Alcohol Withdrawal, Lactic Acidosis, Vitamin B1 Deficiency, Magnesium Deficiency, Wernicke Encephalopathy	MAGNESIUM SULFATE, THIAMINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 21

See all 21 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Phenobarbital Group vs Placebo Group: Number of Patients Requiring Continuous Lorazepam Infusion	2 of 51	16 of 51	102	NCT01184417	Trial comparisons
Phenobarbital Group vs Placebo Group: Number of Study Patients With Seizure as a Measure of Safety and Tolerability	1 of 51	2 of 51	102	NCT01184417	Trial comparisons
Phenobarbital Group vs Placebo Group: Number of Patients Requiring Endotracheal Intubation as a Measure of Safety and Tolerability	0 of 51	0 of 51	102	NCT01184417	Trial comparisons
Phenobarbital Group vs Placebo Group: Number of Study Patients With Mortality as a Measure of Safety and Tolerability	0 of 51	0 of 51	102	NCT01184417	Trial comparisons
Phenobarbital Group vs Placebo Group: serious adverse events	0 of 51	0 of 51	102	NCT01184417	Trial comparisons
Acamprosate vs Placebo: serious adverse events	1 of 23	0 of 26	49	NCT00106106	Trial comparisons
Baclofen vs Placebo: serious adverse events	2 of 25	1 of 19	44	NCT00597701	Trial comparisons
Intranasal Spray Without Oxytocin vs Intranasal Oxytocin Spray: serious adverse events	0 of 6	0 of 8	14	NCT01212185	Trial comparisons

Papers from its trials12

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32053696	RESULT	1	PubMed
30784955	RESULT	1	PubMed
30146330	RESULT	1	PubMed
21631542	RESULT	1	PubMed
19593171	RESULT	1	PubMed
19560604	RESULT	1	PubMed
35484175	DERIVED	1	PubMed
30280905	DERIVED	1	PubMed
29960116	DERIVED	1	PubMed
22898443	DERIVED	1	PubMed

1 to 10 of 12

See all 12 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005433

GET https://conductscience.org/api/diseases/v1/MONDO_0005433/drugs?page=2

API reference For AI assistants